107 related articles for article (PubMed ID: 15898348)
1. Pyridoxamine (BioStratum).
Giannoukakis N
Curr Opin Investig Drugs; 2005 Apr; 6(4):410-8. PubMed ID: 15898348
[TBL] [Abstract][Full Text] [Related]
2. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
3. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Coughlan MT; Cooper ME; Forbes JM
Ann N Y Acad Sci; 2005 Jun; 1043():750-8. PubMed ID: 16037302
[TBL] [Abstract][Full Text] [Related]
4. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
[TBL] [Abstract][Full Text] [Related]
5. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
[TBL] [Abstract][Full Text] [Related]
6. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Williams ME; Bolton WK; Khalifah RG; Degenhardt TP; Schotzinger RJ; McGill JB
Am J Nephrol; 2007; 27(6):605-14. PubMed ID: 17823506
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced glycation (AGE) and lipoxidation (ALE) end products.
Culbertson SM; Enright GD; Ingold KU
Org Lett; 2003 Jul; 5(15):2659-62. PubMed ID: 12868883
[TBL] [Abstract][Full Text] [Related]
8. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Khalifah RG; Chen Y; Wassenberg JJ
Ann N Y Acad Sci; 2005 Jun; 1043():793-806. PubMed ID: 16037307
[TBL] [Abstract][Full Text] [Related]
9. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.
Khalifah RG; Baynes JW; Hudson BG
Biochem Biophys Res Commun; 1999 Apr; 257(2):251-8. PubMed ID: 10198198
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats.
Waanders F; van den Berg E; Nagai R; van Veen I; Navis G; van Goor H
Nephrol Dial Transplant; 2008 Feb; 23(2):518-24. PubMed ID: 17905804
[TBL] [Abstract][Full Text] [Related]
11. New therapies for advanced glycation end product nephrotoxicity: current challenges.
Williams ME
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S42-7. PubMed ID: 12612951
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxamine: the many virtues of a maillard reaction inhibitor.
Voziyan PA; Hudson BG
Ann N Y Acad Sci; 2005 Jun; 1043():807-16. PubMed ID: 16037308
[TBL] [Abstract][Full Text] [Related]
13. [Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Yamagishi S; Imaizumi T
Nihon Rinsho; 2005 Jun; 63 Suppl 6():136-8. PubMed ID: 15999696
[No Abstract] [Full Text] [Related]
14. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.
Chetyrkin SV; Zhang W; Hudson BG; Serianni AS; Voziyan PA
Biochemistry; 2008 Jan; 47(3):997-1006. PubMed ID: 18161948
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Cameron NE; Gibson TM; Nangle MR; Cotter MA
Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
[TBL] [Abstract][Full Text] [Related]
16. The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect.
Adrover M; Vilanova B; Frau J; Muñoz F; Donoso J
Bioorg Med Chem; 2008 May; 16(10):5557-69. PubMed ID: 18434162
[TBL] [Abstract][Full Text] [Related]
17. New potential agents in treating diabetic kidney disease: the fourth act.
Williams ME
Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.
Takeuchi M; Yamagishi S; Iwaki M; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2004; 24(2-3):95-101. PubMed ID: 15689055
[TBL] [Abstract][Full Text] [Related]
19. Vitamin B6 (pyridoxamine) supplementation and complications of diabetes.
Jain SK
Metabolism; 2007 Feb; 56(2):168-71. PubMed ID: 17224328
[No Abstract] [Full Text] [Related]
20. Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy.
Chen JL; Francis J
J Am Soc Nephrol; 2012 Jan; 23(1):6-8. PubMed ID: 22158434
[No Abstract] [Full Text] [Related]
[Next] [New Search]
